Viral Genetics:VRAL Achieves unprecedented AIDS breakthrough! VIRAL GENETICS, INC. 	December, 2001 HIGHLIGHTS *	Viral Genetics has developed a revolutionary new technology called TNP which, based  on clinical results to date, not only  stops but also reverses the progression of HIV infection in people. *	TNP is an extracted, naturally occurring, biologically active linear protein which, when  purified and modified, greatly  stimulates the body's immune response system. *	Three months after an eight week TNP treatment, 8 out of 10 terminally ill AIDS  patients in clinical trials show virtually no  sign of HIV infection. *	TNP treated patients display virtually no side effects to treatment. *	TNP technology is patented in 16 countries and patent pending in Canada and the U.S. *	Treatments are far less costly and less cumbersome than currently employed  alternatives. OVERVIEW Viral Genetics, Inc. was founded in 1995 to develop and commercialize therapeutic and  diagnostic systems for the treatment of  viral diseases.  Their primary focus has been on finding a treatment which would stop and  reverse the progression of HIV  infection in humans.  After expenditures in excess of $8M, Viral Genetics developed their  core technology - TNP (Thymus  Nuclear Protein). Since TNP's discovery, Viral Genetics has conducted numerous animal studies and three  human clinical trials.  Each human trial  consisted of 10 to 20 patients in the late stages of infection.  TNP was administered by intra- muscular injection bi-weekly over  an eight week period.  Follow up was carried out on all the patients anywhere from 50 to  667 days after treatment.  The trials  revealed the following incredible results with respect to TNP's efficacy and safety: -	HIV viral levels were reduced by 90% even 18 months after treatment. -	Patients experienced minimal side effects during treatment which completely subsided  after treatment and remained that way  even 18 months after treatment. -	Dramatic reductions occurred even with HIV resistant strains that no Antiviral Drug  Cocktail has shown any efficacy with  whatsoever. -	Most patients started to regain body weight during and after TNP treatment. Viral Genetics is in discussions with a number of world wide governments to commercialize  the TNP technology. STRUCTURE 	Listed:	OTCBB	Symbol:	VRAL 	Shares Outstanding:	37.11M	Public Float:	3.20M 	Warrants:	none	Options:	none 	Website:	www.viralgenetics.com 	Recent  Price:	$1.40 	Share Price High:	$3.50	Share Price Low:	$0.40 For further information, please contact: Alternative Capital Group (416) 601-0076